Emergent Biosolutions (EBS) Stock Price Down 8.6% Following Insider Selling

Share on StockTwits

Shares of Emergent Biosolutions Inc (NYSE:EBS) traded down 8.6% during trading on Wednesday following insider selling activity. The stock traded as low as $51.34 and last traded at $52.09. 1,307,910 shares changed hands during mid-day trading, an increase of 206% from the average session volume of 427,847 shares. The stock had previously closed at $56.98.

Specifically, CEO Daniel Abdun-Nabi sold 14,565 shares of the stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $58.11, for a total value of $846,372.15. Following the completion of the sale, the chief executive officer now owns 142,617 shares of the company’s stock, valued at $8,287,473.87. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Adam Havey sold 2,430 shares of the stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $56.93, for a total value of $138,339.90. Following the completion of the sale, the executive vice president now directly owns 32,240 shares of the company’s stock, valued at approximately $1,835,423.20. The disclosure for this sale can be found here. Insiders have sold 58,132 shares of company stock valued at $3,411,113 in the last three months. Insiders own 13.40% of the company’s stock.

Several equities research analysts recently commented on the company. Chardan Capital set a $71.00 price target on Emergent Biosolutions and gave the company a “buy” rating in a report on Friday, February 22nd. TheStreet cut Emergent Biosolutions from a “b+” rating to a “c+” rating in a report on Tuesday. Zacks Investment Research raised Emergent Biosolutions from a “sell” rating to a “hold” rating in a research note on Thursday, February 28th. Cantor Fitzgerald set a $75.00 target price on Emergent Biosolutions and gave the stock a “buy” rating in a research note on Friday, January 4th. Finally, ValuEngine cut Emergent Biosolutions from a “buy” rating to a “hold” rating in a research note on Friday, March 1st. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $70.43.

The company has a debt-to-equity ratio of 0.78, a current ratio of 3.10 and a quick ratio of 2.07. The company has a market capitalization of $2.92 billion, a PE ratio of 21.70, a price-to-earnings-growth ratio of 0.87 and a beta of 1.36.

Emergent Biosolutions (NYSE:EBS) last posted its earnings results on Thursday, February 21st. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.61 by $0.14. The company had revenue of $270.70 million during the quarter, compared to analysts’ expectations of $269.05 million. Emergent Biosolutions had a return on equity of 12.61% and a net margin of 8.02%. The firm’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.74 earnings per share. On average, research analysts anticipate that Emergent Biosolutions Inc will post 3.27 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of EBS. Bank of New York Mellon Corp boosted its position in shares of Emergent Biosolutions by 2.3% during the second quarter. Bank of New York Mellon Corp now owns 755,948 shares of the biopharmaceutical company’s stock worth $38,167,000 after buying an additional 16,801 shares during the period. Wells Fargo & Company MN boosted its position in shares of Emergent Biosolutions by 6.8% during the third quarter. Wells Fargo & Company MN now owns 146,984 shares of the biopharmaceutical company’s stock worth $9,676,000 after buying an additional 9,395 shares during the period. Dupont Capital Management Corp boosted its position in shares of Emergent Biosolutions by 136.7% during the third quarter. Dupont Capital Management Corp now owns 33,739 shares of the biopharmaceutical company’s stock worth $2,221,000 after buying an additional 19,486 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Emergent Biosolutions by 22.8% during the third quarter. JPMorgan Chase & Co. now owns 26,779 shares of the biopharmaceutical company’s stock worth $1,763,000 after buying an additional 4,980 shares during the period. Finally, Prudential Financial Inc. boosted its position in shares of Emergent Biosolutions by 86.1% during the third quarter. Prudential Financial Inc. now owns 336,554 shares of the biopharmaceutical company’s stock worth $22,156,000 after buying an additional 155,666 shares during the period. 83.52% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: This story was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this story on another domain, it was stolen and republished in violation of US and international trademark and copyright law. The original version of this story can be accessed at https://weekherald.com/2019/03/15/emergent-biosolutions-ebs-stock-price-down-8-6-following-insider-selling.html.

About Emergent Biosolutions (NYSE:EBS)

Emergent BioSolutions Inc focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. Its products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases.

Featured Article: Dividend Aristocrat Index

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.